GHRP-6

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that acts as an agonist at the growth hormone secretagogue receptor (GHS-R1a), the same receptor activated by endogenous ghrelin. It triggers a rapid, dose-dependent pulse of growth hormone from the anterior pituitary and, secondarily, stimulates the release of other hormones including prolactin, ACTH, and cortisol. GHRP-6 was the first member of the GHRP family to be widely characterized and remains in use as a research tool and in the wellness community for GH optimization protocols.

Unlike GHRH analogs (Sermorelin, CJC-1295), which act on the GHRH receptor, GHRP-6 works through a parallel pathway by mimicking ghrelin. This means it can be combined with a GHRH analog to produce a synergistic GH response — the two signals together yield more GH release than either alone. Because of this, the combination of GHRP-6 with CJC-1295 (Mod GRF 1-29) was historically a popular stack before cleaner, more selective ghrelin agonists like Ipamorelin became widely available.

A signature feature of GHRP-6 is its strong activation of appetite via the same ghrelin-receptor pathway. This makes it useful in research models of cachexia, anorexia, or recovery from illness where increased food intake is desirable, but it can be an unwanted side effect in lean-out or body-recomposition contexts.

GHRP-6 was developed in 1984 by Cyril Y. Bowers at Tulane University as part of a systematic effort to identify synthetic compounds that release growth hormone via mechanisms distinct from GHRH. Its characterization in the late 1980s helped establish the existence of a separate growth hormone secretagogue receptor — later identified in 1996 as GHS-R1a — and ultimately led to the discovery of endogenous ghrelin in 1999 by Kojima and Kangawa. GHRP-6 thus has historical significance well beyond its own clinical use: it was the probe that pointed the field toward an entirely new endocrine axis.